Utilizing Population Pharmacokinetic Analysis & Exposure-Response (ER) Analysis to Better Inform Dosing
Time: 3:30 pm
day: Conference Day 2
Details:
- Enhancing characterization of doses prior to registration trials to maximize the efficacy and safety of oncology drugs
- Assess the impact of Covariates (Intrinsic and Extrinsic factors) on ADC exposure and on optimal dose
- PopPK and Quantitative Medicine-based Optimal Dose and Schedule for ADCs and combinations
